Sarepta Reports Favorable Safety Results from Phase I Study of AVI-7100
September 30, 2014 at 07:32 AM EDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results ...